Sridhar Nimmagadda
Overview
Explore the profile of Sridhar Nimmagadda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
3010
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mishra A, Sharma A, Gupta K, Banka D, Johnson B, Hoffman-Censits J, et al.
bioRxiv
. 2025 Jan;
PMID: 39763905
The optimization of dosing strategies is critical for maximizing efficacy and minimizing toxicity in drug development, particularly for drugs with narrow therapeutic windows such as antibody-drug conjugates (ADCs). This study...
2.
Ludwig S, Meksiriporn B, Tan J, Kureshi R, Mishra A, Kaeo K, et al.
Cell Chem Biol
. 2024 Apr;
31(5):1023.
PMID: 38679021
No abstract available.
3.
Ludwig S, Meksiriporn B, Tan J, Kureshi R, Mishra A, Kaeo K, et al.
Cell Chem Biol
. 2024 Mar;
31(5):904-919.e11.
PMID: 38547863
Programmed death-ligand 1 (PD-L1) drives inhibition of antigen-specific T cell responses through engagement of its receptor programmed death-1 (PD-1) on activated T cells. Overexpression of these immune checkpoint proteins in...
4.
Sharma A, Gupta K, Mishra A, Lofland G, Marsh I, Kumar D, et al.
Adv Sci (Weinh)
. 2024 Feb;
11(16):e2308617.
PMID: 38421139
The limited availability of molecularly targeted low-molecular-weight imaging agents for monitoring multiple myeloma (MM)-targeted therapies has been a significant challenge in the field. In response, a first-in-class peptide-based radiotracer, [Ga]Ga-AJ206,...
5.
Oldan J, Schroeder J, Hoffman-Censits J, Rathmell W, Milowsky M, Solnes L, et al.
PET Clin
. 2024 Jan;
19(2):197-206.
PMID: 38199916
Renal cell carcinoma (RCC) and urothelial carcinoma (UC) are two of the most common genitourinary malignancies. 2-deoxy-2-[18F]fluoro-d-glucose (18F-FDG) can play an important role in the evaluation of patients with RCC...
6.
Vu T, Kim K, Manna M, Thomas J, Remaily B, Montgomery E, et al.
Pharmacol Res
. 2023 Dec;
199:107048.
PMID: 38145833
High baseline clearance of immune checkpoint inhibitors (ICIs), independent of dose or systemic exposure, is associated with cachexia and poor outcomes in cancer patients. Mechanisms linking ICI clearance, cachexia and...
7.
Mishra A, Gupta K, Kumar D, Lofland G, Sharma A, Solnes L, et al.
J Immunother Cancer
. 2023 Oct;
11(10).
PMID: 37793856
Background: Combination therapies that aim to improve the clinical efficacy to immune checkpoint inhibitors have led to the need for non-invasive and early pharmacodynamic biomarkers. Positron emission tomography (PET) is...
8.
Leland P, Kumar D, Nimmagadda S, Bauer S, Puri R, Joshi B
J Transl Med
. 2023 Sep;
21(1):636.
PMID: 37726828
No abstract available.
9.
Parkins K, Krishnamachary B, Jacob D, Kakkad S, Solaiyappan M, Mishra A, et al.
Radiol Imaging Cancer
. 2023 Jun;
5(4):e220138.
PMID: 37389448
Purpose To examine the association between hypoxia and programmed cell death ligand 1 (PD-L1) expression using bioluminescence imaging (BLI) and PET/MRI in a syngeneic mouse model of triple-negative breast cancer...
10.
Leland P, Kumar D, Nimmagadda S, Bauer S, Puri R, Joshi B
J Transl Med
. 2023 Jun;
21(1):367.
PMID: 37286997
Background: Chimeric antigen receptor (CAR) T cell therapy is an exciting cell-based cancer immunotherapy. Unfortunately, CAR-T cell therapy is associated with serious toxicities such as cytokine release syndrome (CRS) and...